Published in Medical Letter on the CDC and FDA, September 28th, 2008
Commenting on this approval MiCardia Chief Executive Officer, Paul Molloy said, "This is a key regulatory milestone for MiCardia which involved extensive technical validation of the Company's first generation annuloplasty system. It prepares the way for the progression of this highly unique and innovative Dynaplasty Technology and pairs with the commencement of the Company's DYANA...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA